Aclaris Therapeutics (NASDAQ: ACRS) and Paratek Pharmaceuticals (NASDAQ:PRTK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitabiliy and risk.
This table compares Aclaris Therapeutics and Paratek Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Aclaris Therapeutics has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Comparatively, Paratek Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Insider and Institutional Ownership
91.4% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of Paratek Pharmaceuticals shares are owned by institutional investors. 16.3% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 4.9% of Paratek Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Aclaris Therapeutics and Paratek Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Aclaris Therapeutics||N/A||N/A||-$47.58 million||($2.09)||-12.20|
|Paratek Pharmaceuticals||$46,999.00||13,157.99||-$103.85 million||($5.03)||-4.47|
Aclaris Therapeutics has higher revenue, but lower earnings than Paratek Pharmaceuticals. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Paratek Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for Aclaris Therapeutics and Paratek Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aclaris Therapeutics currently has a consensus price target of $40.00, indicating a potential upside of 56.92%. Paratek Pharmaceuticals has a consensus price target of $38.22, indicating a potential upside of 69.88%. Given Paratek Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Paratek Pharmaceuticals is more favorable than Aclaris Therapeutics.
Aclaris Therapeutics beats Paratek Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK). It has completed approximately three Phase II clinical trials of A-101. It has initiated over two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK. It also intends to develop A-101 as a prescription treatment for common warts, also known as verruca vulgaris, and A-102, a gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. It has initiated a Phase II clinical trial to evaluate A-101 for the treatment of common warts.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.